Pancreatic Cancer Research

ResearcherNovartis PharmaceuticalsNo recent work listed

Novartis Pharmaceuticals

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 9 November 2026

Known by name at one institution; no external author ID yet. Sources: ClinicalTrials.gov.

Their work

Papers
0
Trials
24
Grants
0
Labs led
0
Collaborators
0
Papers, trials and grants by year

2002: 1 trial · 2003: none · 2004: none · 2005: none · 2006: 1 trial · 2007: 2 trials · 2008: none · 2009: 1 trial · 2010: 1 trial · 2011: 3 trials · 2012: 3 trials · 2013: none · 2014: 1 trial · 2015: none · 2016: 3 trials · 2017: 2 trials · 2018: 1 trial · 2019: none · 2020: none · 2021: 4 trials · 2022: none · 2023: 1 trial

Trials 24

  1. A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. Study director NCT05977322↗
  2. Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. Study director NCT04712721↗
  3. Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs Study director NCT04727723↗
  4. Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC… Study director NCT04935359↗
  5. A Study of 177Lu-FAP-2286 in Advanced Solid Tumors Study director NCT04939610↗
  6. A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. Study director NCT03549000↗
  7. Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. Study director NCT02947165↗
  8. Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastro… Study director NCT02955069↗
  9. Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors Study director NCT02703571↗
  10. Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies Study director NCT02807844↗
  11. Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Study director NCT02842749↗
  12. Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and… Study director NCT02077933↗
  13. Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients Study director NCT01487785↗
  14. Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors Study director NCT01628913↗
  15. BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. Study director NCT01658436↗
  16. A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Study director NCT01351103↗
  17. Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET Study director NCT01374451↗
  18. Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas Study director NCT01433263↗
  19. A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients Study director NCT01155453↗
  20. Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Study director NCT00958841↗
  21. Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors Study director NCT00510068↗
  22. Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine Study director NCT00560963↗
  23. Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy Study director NCT00363051↗
  24. EPO906 in Carcinoid and Other Neuroendocrine Tumors Study director NCT00050349↗

Closest collaborators

No collaborators recorded.

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.